Pharmaceutical companies to benefit from new blood cancer drugs The Pharma Letter ... (ibrutinib) will be among the biggest products in blood cancer treatments, and has recently been approved for CLL, while Roche/Biogen Idec's Gazyva (obinutuzumab) could eventually more than replace its lucrative but mature Rituxan(rituximab ... |
